{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:43:06Z","timestamp":1785307386415,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Autoimmune liver diseases (AILD) are increasing and common forms of chronic liver disease (CLD) with different clinical responses and characteristics which can result in cirrhosis. This study aimed to investigate the natural history and characteristics of AILD in an Iranian population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with AILD [Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) and Overlap Syndrome (OS)] referred to Middle East Liver Diseases (MELD) center, Tehran, Iran, between January 2002 and December 2022 were included in this retrospective cohort study. The main features of natural history (the trends of liver functional tests (LFT), Auto-Antibodies, response to treatment and cirrhotic status) along with demographic data were studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two hundred sixty-five patients (160 (60.4%) AIH, 37 (14.0%) PBC, 20 (7.5%) PSC, 48 (18.1%) overlap syndrome) with a median follow-up time of 5 years (IQR 4 to 8 years) were included. Baseline laboratory tests revealed that patients with AIH exhibit elevated transaminase levels. However, patients suffering from PBC and PSC displayed increased alkaline phosphatase levels. Conversely, in overlap syndrome patients, both transaminases and alkaline phosphatase were observed at high levels. Autoantibodies represented themselves as important diagnostic markers for the AIH and PBC but not for PSC. The complete response occurred in 112 (70%) of and 28 (58.4%) patients with AIH and overlap syndrome respectively and 21 patients 11 (6.9%) of AIH and 10 (20.8%) of overlap syndrome) were non-responders. Other patients in these two categories were considered as insufficient responders. On the other side, 32 (91.9%) and 8 (40%) of patients with PBC and PSC biochemically responded to Ursodeoxycholic Acid (UDCA). Unpredictably, cirrhosis regression was observed in some AIH and PBC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Appropriate medication management for AILD patients may leads to regression from cirrhosis and improvement of manifestations; while discontinuation of medication may cause relapses. However, patient suffering from PSC showed limited response to treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-03105-7","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T14:02:06Z","timestamp":1704376926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center"],"prefix":"10.1186","volume":"24","author":[{"given":"Seyed Erfan Mehdi","family":"Nejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Heiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Javanbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Moayed","family":"Alavian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali Abyazi","family":"Haris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"1","key":"3105_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","volume":"60","author":"M Carbone","year":"2014","unstructured":"Carbone M, Neuberger JM. Autoimmune Liver Disease, autoimmunity and liver transplantation. J Hepatol. 2014;60(1):210\u201323.","journal-title":"J Hepatol"},{"issue":"31","key":"3105_CR2","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.3748\/wjg.v28.i31.4417","volume":"28","author":"ZX Shen","year":"2022","unstructured":"Shen ZX, et al. Prevalence and clinical characteristics of autoimmune Liver Disease in hospitalized patients with Cirrhosis and acute decompensation in China. World J Gastroenterol. 2022;28(31):4417\u201330.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"3105_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/jpm12060925","volume":"12","author":"F Invernizzi","year":"2022","unstructured":"Invernizzi F, et al. Gender and autoimmune Liver Diseases: relevant aspects in clinical practice. J Personalized Med. 2022;12(6):925.","journal-title":"J Personalized Med"},{"issue":"12","key":"3105_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.5152\/tjg.2020.19866","volume":"31","author":"N Demir","year":"2020","unstructured":"Demir N, et al. Two decades of research on autoimmune Liver Disease in Turkey. Turkish J Gastroenterol. 2020;31(12):877\u201382.","journal-title":"Turkish J Gastroenterol"},{"issue":"1","key":"3105_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3350\/cmh.2020.0189","volume":"27","author":"A Komori","year":"2021","unstructured":"Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol. 2021;27(1):58.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"3105_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3350\/cmh.2022.0387","volume":"29","author":"NY Heo","year":"2023","unstructured":"Heo NY, Kim H. Epidemiology and updated management for autoimmune Liver Disease. Clin Mol Hepatol. 2023;29(1):194\u20136.","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"3105_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cgh.2020.05.061","volume":"19","author":"M Lamba","year":"2021","unstructured":"Lamba M, Ngu JH, Stedman CAM. Trends in incidence of Autoimmune Liver Diseases and increasing incidence of Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2021;19(3):573\u2013579e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"3105_CR8","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.cgh.2021.01.029","volume":"19","author":"GJ Webb","year":"2021","unstructured":"Webb GJ, et al. The epidemiology of UK Autoimmune Liver Disease varies with Geographic Latitude. Clin Gastroenterol Hepatol. 2021;19(12):2587\u201396.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"3105_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12072-016-9767-9","volume":"10","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, et al. Autoimmune Liver Diseases in the Asia\u2013Pacific region: proceedings of APASL symposium on AIH and PBC 2016. Hep Intl. 2016;10(6):909\u201315.","journal-title":"Hep Intl"},{"issue":"10","key":"3105_CR10","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","volume":"70","author":"PJ Trivedi","year":"2021","unstructured":"Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune Liver Diseases. Gut. 2021;70(10):1989\u20132003.","journal-title":"Gut"},{"issue":"1","key":"3105_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169\u201376.","journal-title":"Hepatology"},{"issue":"5","key":"3105_CR12","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/hep.22825","volume":"49","author":"P Muratori","year":"2009","unstructured":"Muratori P, et al. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology. 2009;49(5):1782\u20133. author reply 1783.","journal-title":"Hepatology"},{"issue":"23","key":"3105_CR13","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.3748\/wjg.v19.i23.3629","volume":"19","author":"MR Abdollahi","year":"2013","unstructured":"Abdollahi MR, Somi MH, Faraji E. Role of international criteria in the diagnosis of autoimmune hepatitis. World J Gastroenterol. 2013;19(23):3629\u201333.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"3105_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.aohep.2018.09.001","volume":"18","author":"AA Aljumah","year":"2019","unstructured":"Aljumah AA, et al. Acute onset autoimmune hepatitis: clinical presentation and treatment outcomes. Ann Hepatol. 2019;18(3):439\u201344.","journal-title":"Ann Hepatol"},{"issue":"4","key":"3105_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.1840180435","volume":"18","author":"PJ Johnson","year":"1993","unstructured":"Johnson PJ, McFarlane IG. o.t.P. Convenors, Meeting report: international autoimmune hepatitis group. Hepatology. 1993;18(4):998\u20131005.","journal-title":"Hepatology"},{"issue":"3","key":"3105_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary Cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130(3):715\u201320.","journal-title":"Gastroenterology"},{"issue":"3","key":"3105_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808\u201314.","journal-title":"Hepatology"},{"issue":"6","key":"3105_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","volume":"42","author":"S Lemoinne","year":"2018","unstructured":"Lemoinne S, et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French\u2013Spanish experience. Clin Res Hepatol Gastroenterol. 2018;42(6):521\u20138.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9596","key":"3105_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, et al. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet. 2007;370(9596):1453\u20137.","journal-title":"The Lancet"},{"issue":"2","key":"3105_CR20","first-page":"87","volume":"41","author":"GS D\u00edaz-Ram\u00edrez","year":"2018","unstructured":"D\u00edaz-Ram\u00edrez GS, et al. Characterization of patients with autoimmune hepatitis at a university hospital in Medell\u00edn-Colombia: Cohort study Gastroenterolog\u00eda Y Hepatolog\u00eda. (English Edition). 2018;41(2):87\u201396.","journal-title":"(English Edition)"},{"key":"3105_CR21","doi-asserted-by":"crossref","unstructured":"Granito A, et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Volume 21. Alimentary pharmacology & therapeutics; 2005;1273\u20137. 10.","DOI":"10.1111\/j.1365-2036.2005.02488.x"},{"key":"3105_CR22","doi-asserted-by":"crossref","unstructured":"Al-Chalabi T, et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long\u2010term outcome and survival. Alimentary pharmacology & therapeutics; 2008;28(2):209\u201320.","DOI":"10.1111\/j.1365-2036.2008.03722.x"},{"issue":"9","key":"3105_CR23","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1111\/liv.15155","volume":"42","author":"T Katsumi","year":"2022","unstructured":"Katsumi T, Ueno Y. Epidemiology and surveillance of autoimmune hepatitis in Asia. Liver Int. 2022;42(9):2015\u201322.","journal-title":"Liver Int"},{"key":"3105_CR24","doi-asserted-by":"crossref","unstructured":"Floreani A, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Alimentary pharmacology & therapeutics; 2006;24(7):1051\u20137.","DOI":"10.1111\/j.1365-2036.2006.03104.x"},{"key":"3105_CR25","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.curtheres.2020.100594","volume":"93","author":"MIC Fern\u00e1ndez","year":"2020","unstructured":"Fern\u00e1ndez MIC, et al. Autoimmune Hepatitis in Cuban patients: a retrospective analysis of clinical and histological profiles, treatments, and outcomes. Curr Therapeutic Res. 2020;93:100594.","journal-title":"Curr Therapeutic Res"},{"issue":"2","key":"3105_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/jcm12020629","volume":"12","author":"TA Tamimi","year":"2023","unstructured":"Tamimi TA, et al. Clinical characteristics of Autoimmune Hepatitis in a Middle Eastern Population: a Tertiary Care Center Experience. J Clin Med. 2023;12(2):629.","journal-title":"J Clin Med"},{"issue":"10","key":"3105_CR27","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","volume":"49","author":"NM van Gerven","year":"2014","unstructured":"van Gerven NM, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49(10):1245\u201354.","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"3105_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1872-034X.2011.00844.x","volume":"41","author":"A Tanaka","year":"2011","unstructured":"Tanaka A, et al. Primary biliary Cirrhosis\u2013autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res. 2011;41(9):877\u201386.","journal-title":"Hepatol Res"},{"issue":"9","key":"3105_CR29","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.dld.2019.01.015","volume":"51","author":"L Puustinen","year":"2019","unstructured":"Puustinen L, et al. Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: a nationwide register-based cohort study in Finland. Dig Liver Disease. 2019;51(9):1294\u20139.","journal-title":"Dig Liver Disease"},{"issue":"10","key":"3105_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s40265-021-01545-7","volume":"81","author":"S Hasegawa","year":"2021","unstructured":"Hasegawa S, et al. Cholestatic Liver Disease: current treatment strategies and new therapeutic agents. Drugs. 2021;81(10):1181\u201392.","journal-title":"Drugs"},{"issue":"7","key":"3105_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/MEG.0b013e328331c2b7","volume":"22","author":"A Garioud","year":"2010","unstructured":"Garioud A, et al. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22(7):842\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3105_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s10620-019-05484-y","volume":"64","author":"ZP Fricker","year":"2019","unstructured":"Fricker ZP, Lichtenstein DR. Primary sclerosing cholangitis: a concise review of diagnosis and management. Dig Dis Sci. 2019;64:632\u201342.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3105_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2020.0028","volume":"27","author":"A Tanaka","year":"2021","unstructured":"Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol. 2021;27(1):1.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"3105_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3138\/canlivj-2021-0023","volume":"5","author":"F Peerani","year":"2022","unstructured":"Peerani F, et al. Serum IgG4 cut-off of 70\u00a0mg\/dL is associated with a shorter time to Cirrhosis decompensation and liver transplantation in primary sclerosing cholangitis patients. Can Liver J. 2022;5(1):31\u201342.","journal-title":"Can Liver J"},{"issue":"11\u201312","key":"3105_CR35","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/j.1365-2036.2006.03172.x","volume":"24","author":"A Granito","year":"2006","unstructured":"Granito A, et al. Antinuclear antibodies giving the \u2018multiple nuclear dots\u2019 or the \u2018rim-like\/membranous\u2019 patterns: diagnostic accuracy for primary biliary Cirrhosis. Aliment Pharmacol Ther. 2006;24(11\u201312):1575\u201383.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3105_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.14218\/JCTH.2020.00036","volume":"8","author":"S Mago","year":"2020","unstructured":"Mago S, Wu GY. Primary sclerosing Cholangitis and primary biliary Cirrhosis overlap syndrome: a review. J Clin Transl Hepatol. 2020;8(3):336\u201346.","journal-title":"J Clin Transl Hepatol"},{"issue":"8","key":"3105_CR37","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","volume":"20","author":"PJ Trivedi","year":"2022","unstructured":"Trivedi PJ, et al. Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of Population-based studies. Clin Gastroenterol Hepatol. 2022;20(8):1687\u20131700e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3105_CR38","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/liv.12560","volume":"35","author":"C Quarneti","year":"2015","unstructured":"Quarneti C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary Cirrhosis. Liver Int. 2015;35(2):636\u201341.","journal-title":"Liver Int"},{"issue":"1","key":"3105_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10620-006-9495-4","volume":"52","author":"P Muratori","year":"2007","unstructured":"Muratori P, et al. Evidence of a genetic basis for the different geographic occurrences of liver\/kidney microsomal antibody type 1 in Hepatitis C. Dig Dis Sci. 2007;52(1):179\u201384.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"3105_CR40","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1159\/000366174","volume":"32","author":"GJ Webb","year":"2014","unstructured":"Webb GJ, Hirschfield GM. Genetics of autoimmune Liver Disease: a brief summary for clinicians. Dig Dis. 2014;32(5):e1\u20136.","journal-title":"Dig Dis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03105-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03105-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T14:04:22Z","timestamp":1704377062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03105-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3105"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03105-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"8 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of Baqiyatallah Hospital (Approval ID: IR.BMSU.BAQ.REC.1401.055). All the experiments of this study were conducted in accordance to the relevant guidelines and regulations and in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration. Informed consent was obtained from all the participants for the participation in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}